EGFR tyrosine kinase inhibitors (EGFR-TKIs), such as erlotinib or gefitinib, mainly function through blocking the ATP-binding pocket of the EGFR and suppressing two major signaling pathways in cancer - PI3K/Akt and Ras/MAPK pathway5. Here, EGFR is linked to cancer.